Research Article
Positive ALDH1A3 and Negative GPX3 Expressions Are Biomarkers for Poor Prognosis of Gallbladder Cancer
Table 2
Relationship between ALDH1A3 and GPX3 expressions, clinicopathological characteristics, and average survival of SC/ASC and AC patients.
| C.P characteristics | Samples | Average survival (month) | Chi-square | value |
| SC/ASC | | | | | Differentiation | | | | | Well | 16 | 13.81 (5–24) | 19.125 | 0.000 | Moderately | 24 | 8.92 (4–18) | Poorly | 6 | 5.83 (4–9) | Tumor mass size | | | | | ≤3 cm | 20 | 14.35 (7–24) | 31.337 | 0.000 | >3 cm | 26 | 7.04 (4–11) | TNM stage | | | | | I + II | 12 | 17.00 (9–24) | 51.139 | 0.000 | III | 20 | 9.20 (7–15) | IV | 14 | 5.86 (4–8) | Lymph node metastasis | | | | | No | 17 | 14.24 (4–24) | 16.219 | 0.000 | Yes | 29 | 7.86 (4–15) | Invasion | | | | | No | 16 | 15.75 (9–24) | 32.271 | 0.000 | Yes | 30 | 7.27 (4–12) | Surgery | | | | | Radical | 14 | 16.64 (10–24) | 50.165 | 0.000 | Palliative | 18 | 8.50 (6–12) | Biopsy | 14 | 6.00 (4–8) | ALDH1A3 | | | | | − | 30 | 11.67 (6–24) | 7.914 | 0.005 | + | 16 | 7.50 (4–15) | GPX3 | | | | | − | 27 | 8.00 (4–15) | 9.917 | 0.002 | + | 19 | 13.69 (7–24) | AC | | | | | Differentiation | | | | | Well | 27 | 15.07 (5–24) | 32.501 | 0.000 | Moderately | 25 | 10.60 (4–24) | Poorly | 28 | 6.68 (3–14) | Tumor mass size | | | | | ≤3 cm | 50 | 13.70 (6–24) | 68.283 | 0.000 | >3 cm | 30 | 5.80 (3–10) | TNM stage | | | | | I + II | 21 | 18.96 (5–24) | 105.825 | 0.000 | III | 38 | 9.29 (6–15) | IV | 21 | 5.14 (3–7) | Lymph node metastasis | | | | | No | 30 | 16.27 (4–24) | 42.372 | 0.000 | Yes | 50 | 7.42 (3–14) | Invasion | | | | | No | 31 | 16.68 (7–24) | 55.535 | 0.000 | Yes | 49 | 6.98 (3–11) | Surgery | | | | | Radical | 26 | 18.31 (10–24) | 113.141 | 0.000 | Palliative | 28 | 8.64 (6–11) | Biopsy | 26 | 5.42 (3–9) | ALDH1A3 | | | | | − | 45 | 13.36 (6–24) | 25.229 | 0.000 | + | 35 | 7.37 (3–18) | GPX3 | | | | | − | 42 | 7.05 (3–15) | 40.507 | 0.000 | + | 38 | 14.82 (5–24) |
|
|
C.P: clinicopathological.
|